References

Chapter 1  To screen or not to screen – first do no harm

1.    Wilson JM, Jungner G. Principles and practices of screening for disease. WHO, Geneva, 1968. whqlibdoc.who.int/php/WHO_PHP_34.pdf

2.    Prescan. www.prescan.co.uk/

3.    Lifescan. www.lifescanuk.org/

4.    Welch, G. Should I Be Tested for Cancer? Maybe not and here’s why. University of California Press. 2004

5.    McCartney M. Executive health checks raise questions. FT Magazine, December 2008.

6.    Vernooij MW, Arfan Ikram M. Incidental Findings on Brain MRI in the General Population. N Engl J Med 2007; 357:1821-1828 www.nejm.org/doi/full/10.1056/NEJMoa070972

7.    Health Technology Assessment. Screening Programs for asymptomatic unruptured intracranial aneurysms: review of clinical effectiveness, cost-effectiveness, and evidence-based guidelines. Canadian Agency for drugs and technologies in Health, May 2010 www.cadth.ca/media/pdf/20100503-090753_l0173_screening_asymptomatic_aneurysms_final.pdf

8.    International Study of Unruptured Intracranial Aneurysms: Unruptured Intracranial Aneurysms – Risk of Rupture and Risks of Surgical Intervention. N Engl J Med 1998; 339:1725-1733 www.nejm.org/doi/full/10.1056/NEJM199812103392401

9.    BUPA Complete Health. www.bupa.co.uk/individuals/health-assessments/complete-health

10.  Ottmar MD, Gonda RL Jr. Liver function tests in patients with computed tomography demonstrated hepatic metastases. Gastrointest Radiol 1989;14: 55-58 www.springerlink.com/content/x6kvhu744u700103/

11.  Aragon G, Younossi ZM. When and how to evaluate mildly elevated liver enzymes in apparently healthy patients. Cleve Clin J Med 2010; 77:195-204. www.ccjm.org/content/77/3/195.long

12.  Sibille M, Deigat N. Laboratory data in healthy volunteers: reference values, reference changes, screening and laboratory adverse event limits in Phase I clinical trials. Eur J Clin Pharmacol 1999; 55:13-9. www.ncbi.nlm.nih.gov/pubmed/10206079

13. Genetichealth ‘Personal Health Management’ website, accessed February 2011 www.genetic-health.co.uk/dna-test-services/premium-female.htm

14. Eeles RA, Stratton MR. The genetics of familial breast cancer and their practical implications. Eur J Cancer 1994; 30: 1383-90 www.sciencedirect.com/science/article/pii/0959804994901902

15.  NICE. CG41: Familial breast cancer. London, 2006. www.nice.org.uk/nicemedia/pdf/CG41NICEguidance.pdf

16.  Lord SJ, Lei W. A systematic review of the effectiveness of MRI as an addition to mammography and ultrasound in screening young women at high risk of breast cancer. Eur J Cancer 2007; 43: 1905-1917 www.ejcancer.info/article/S0959-8049(07)00484-4/abstract

17.  Buys SS, Partridge E. The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA 2011;305(22):2295-2303. jama.ama-assn.org/content/305/22/2295.long

18.  UK Screening Portal, UK National Screening Committee, accessed February 2011 www.screening.nhs.uk/ovariancancer

19.  Margolis J. The Interpretation of Genes. Financial Times, February 2009. www.genetic-health.co.uk/uploadfiles/FT10February2009.pdf

20. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Australia 2009; 190: S54–S60 www.mja.com.au/public/issues/190_07_060409/cla10974_fm.pdf

21.  Scottish Intercollegiate Guidelines Network. SIGN 50: A guideline developer’s handbook. Annex B: key to evidence statements and grades of recommendations. www.sign.ac.uk/guidelines/fulltext/50/annexb.html

22.  More Doctors Smoke Camels Than Any Other Cigarette. 1949 Camel Cigarettes TV commercial. www.youtube.com/watch?v=gCMzjJjuxQI

23.  Gardner MN, Brandt AM. “The doctors’ choice is America’s choice” The physician in US cigarette advertisements, 1930-1953. Am J of Public Health 2006; 96(2):222-232 ajph.aphapublications.org/doi/abs/10.2105/AJPH.2005.066654

24. Dobson R, Elliott J. Dr Spock’s advice blamed for cot deaths. The Times, May 2005. www.timesonline.co.uk/tol/news/uk/health/article520623.ece (£)

25. Gilbert R, Salanti G, Harden M, See S. Infant sleeping position and the sudden infant death syndrome: systematic review of observational studies and historical review ofrecommendations from 1940 to 2002. Int J Epidemio 2005;34:874–887 ije.oxfordjournals.org/content/34/4/874.full.pdf

26.  Hiley CM, Morley C. What do mothers remember about the ‘back to sleep’ campaign?  Arch Dis Child 1995; 73: 496–497 www.ncbi.nlm.nih.gov/pmc/articles/PMC1511461/

27.  Gilbert R, Salanti G. Infant sleeping position and the sudden infant death syndrome: systematic review of observational studies and historical review of recommendations from 1940 to 2002. Int. J. Epidemiol 2005 34: 874-887 ije.oxfordjournals.org/content/34/4/874.full

28.  CRASH trial collaborators. Final results of MRC CRASH, a randomised placebo-controlled trial of intravenous corticosteroid in adults with head injury–outcomes at 6 months. Lancet 2005; 365: 1957-1959 www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)66552-X/abstract

29.  Sauerlanda S, Maegele M. A CRASH landing in severe head injury. Lancet 2004; 364: 1291-1292 www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17202-4/fulltext

30.  Sanossian N, Arbi G. Frequency and Determinants of Nonpublication of Research in the Stroke Literature. Stroke 2006; 37: 2588-2592 stroke.ahajournals.org/content/37/10/2588.full

31.  GlaxoSmithKline. Public disclosure of clinical research. Corporate Responsibility Report, 2010. www.gsk.com/responsibility/cr-report-2010/research-practices/public-disclosure-of-clinical-research/

32.  Krall R, Rockhold F. More on compulsory registration of clinical trials: GSK has created useful register, BMJ 2005;330:479.3, 24th Febuary 2005 www.bmj.com/content/330/7489/479.3.full

33.  Curfman GD, Morrissey S. Expression of Concern: Bombardier et al., “Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in Patients with Rheumatoid Arthritis,” N Engl J Med 2000; 343:1520-8. N Engl J Med, online editorial, December 2008. www.nejm.org/doi/full/10.1056/NEJMe058314

 

Chapter 2  The business of cardiovascular risk

1.    UK election: the main parties’ health policies. Lancet, 375, 9725, 1511-1514, 1 May 2010 www.thelancet.com/journals/lancet/article/PIIS0140-6736(10)60642-3/fulltext

2.    The Scottish Government: Universal health checks planned. March 2010 www.scotland.gov.uk/News/Releases/2010/03/22081937

3.    NHS Choices website, NHS Health Check, accessed February 2011 http://www.nhs.uk/Planners/NHSHealthCheck/Pages/NHSHealthCheckandyou.aspx

4.    NHS The Information Centre. Prescriptions Dispensed in the Community: England, Statistics for 1999 to 2009 Information Centre www.ic.nhs.uk/webfiles/publications/prescriptionsdispensed/Prescriptions_Dispensed_1999_2009%20.pdf

5.    Cholesterol Treatment Trialists’ Collaborators. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins. The Lancet; 366: 1267-1278 www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67394-1/abstract

6.    Thavendiranathan P, Bagai A. Primary Prevention of Cardiovascular Diseases with Statin Therapy. Arch Intern Med 2006; 166: 2307-2313  archinte.ama-assn.org/cgi/content/full/166/21/2307

7.    Graham DJ, Staffa JA. Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs. JAMA 2004 Dec 1;292(21):2585-90. Epub 2004 Nov 22.

8.    Sattar N, Preiss D. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet; 375: 735–742 www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61965-6/abstract

9.    Wenger NK. Preventing cardiovascular disease in women: an update. Clin Cardiol 2008; 31:109-13. onlinelibrary.wiley.com/doi/10.1002/clc.20134/abstract

10.  Abramson J, Wright JM. Are lipid-lowering guidelines evidence-based? Lancet; 369: 168 -169 www.thelancet.com/journals/lancet/article/PIIS0140-6736(07)60084-1/fulltext

11. Samia M, Glynn RJ. Trials. Statins for the Primary Prevention of Cardiovascular Events in Women With Elevated High-Sensitivity C-Reactive Protein or Dyslipidaemia: Results From the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and Meta-Analysis of Women From Primary Prevention Trials. Circulation; 2010: 1069-1077) circ.ahajournals.org/content/121/9/1069

12.  Ford I, Murray H. Long-Term Follow-up of the West of Scotland Coronary Prevention Study. N Engl J Med 2007; 357:1477-1486 www.nejm.org/doi/full/10.1056/NEJMoa065994#t=articleTop

13. Heart Protection Study Collaborative Group, Lancet, 378;9808:2013–2020

14.  British Hypertension Society working party. Treating mild hypertension. BMJ 1989; 298: 694-698 www.ncbi.nlm.nih.gov/pmc/articles/PMC1836038/

15.  Sever P, Beevers G. Management guidelines in essential hypertension: report of the second working party of the British Hypertension Society. BMJ 1993; 306: 983-987 www.ncbi.nlm.nih.gov/pmc/articles/PMC1677457/pdf/bmj00015-0045.pdf

16.  Ramsay LE, Williams B. British Hypertension Society guidelines for hypertension management 1999: summary. BMJ 1999; 319: 630 www.bmj.com/content/319/7210/630.full

17.  Williams B, Poulter NR. British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ 2004; 328: 634 www.bmj.com/content/328/7440/634?view=long&pmid=15016698

18.  NICE. CG127: Clinical management of primary hypertension in adults. London, 2011. www.nice.org.uk/nicemedia/live/13561/56008/56008.pdf

19.  Wright JM, Musini VM. First-line drugs for hypertension. Cochrane Database Syst Rev. 2009; 3: CD001841 onlinelibrary.wiley.com/doi/10.1002/14651858.CD001841.pub2/abstract

20.  Quan A, Kerlikowske K. Pharmacotherapy for hypertension in women of different races. Cochrane Database Syst Rev. 2000; 3: CD002146. onlinelibrary.wiley.com/doi/10.1002/14651858.CD002146/abstract

21.  Musini VM,Tejani AM. Pharmacotherapy for hypertension in the elderly. Cochrane Database Syst Rev. 2009; 4: CD000028 onlinelibrary.wiley.com/doi/10.1002/14651858.CD000028.pub2/abstract

22.  Cranney M, Warren E. Hypertension in the elderly: attitudes of British patients and general practitioners. J Hum Hypertens 1998; 12: 539–545 www.nature.com/jhh/journal/v12/n8/pdf/1000656a.pdf

23.  General Medical Council. Good Medical Practice: Providing good clinical care. www.gmc-uk.org/guidance/good_medical_practice/good_clinical_care_index.asp

 

Chapter 3  The nature of cancer: breast beating

1.    McFarlane MJ, Feinstein AR. The ‘Epidemiologic Necropsy’. Unexpected Detections, Demographic Selections, and Changing Rates of Lung Cancer. JAMA.1987; 258:331-338 jama.ama-assn.org/content/258/3/331.abstract

2.    Sens MA, Zhou X. Unexpected neoplasia in autopsies: potential implications for tissue and organ safety.  Arch Pathol Lab Med. 2009;133:1923-31. www.archivesofpathology.org/doi/full/10.1043/1543-2165-133.12.1923

3.    Veress B, Alafuzoff I. A retrospective analysis of clinical diagnoses and autopsy findings in 3,042 cases during two different time periods. Hum Pathol. 1994; 25:140-5. www.sciencedirect.com/science/article/pii/0046817794902690

4.    Ernster VL, Ballard-Barbash R. Detection of Ductal Carcinoma in Situ in Women Undergoing Screening Mammography. J Natl Cancer Inst 2002; 94: 1546-1554. jnci.oxfordjournals.org/content/94/20/1546.long

5.    NHS Breast Screening Programme. Overcoming Barriers – Annual Review 2010. www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp-annualreview2010.pdf

6.    Sanders ME, Schuyler PA. The natural history of low-grade ductal carcinoma in situ of the breast in women treated by biopsy only revealed over 30 years of long-term follow-up. Cancer 2005; 103: 2481-2484 onlinelibrary.wiley.com/doi/10.1002/cncr.21069/abstract

7.    Virnig BA, Tuttle TM. Ductal carcinoma in situ of the breast: A systematic review of incidence, treatment, and outcomes. J Natl Cancer Inst 2010; 102(3):170-178 jnci.oxfordjournals.org/content/102/3/170.long

8.    Welch HG, Black WC. Using Autopsy Series To Estimate the Disease “Reservoir” for Ductal Carcinoma in Situ of the Breast: How Much More Breast Cancer Can We Find?  Ann Intern Med 1997; 127: 1023-1028 www.annals.org/content/127/11/1023.abstract

9.    Dixon JM. Breast screening has increased the number of mastectomies. Breast Cancer Research 2009, 11(Suppl 3):S19 breast-cancer-research.com/content/11/S3/S19

10.  Flanders J. Reality of ductal carcinoma in situ. BMJ 2009; 338:b958 www.bmj.com/content/338/bmj.b958

11.  Conservative Party. The next moves forward. 1987 www.conservativemanifesto.com/1987/1987-conservative-manifesto.shtml

12.  Currie E. Life Lines. London: Sidgwick and Jackson, 1989

13.  NHS Breast Screening. Department of Health 2011. www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp.pdf

14.  Advisory Committee on Breast Cancer Screening. Screening for breast cancer in England: past and future. J Med Screen 2006;13:59–61 jms.rsmjournals.com/content/13/2/59.full.pdf

15.  Advisory Committee on Breast Cancer Screening. Screening for breast cancer in England: past and future. NHSBSP Publication No 61, 2006 www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp61.pdf

16.  International Agency for Research on Cancer. IARC Handbook of Cancer Prevention Volume 7: Breast Cancer Screening, Chapter 5: Effectiveness of screening. IARC Press, Lyon 2002. www.iarc.fr/en/publications/pdfs-online/prev/handbook7/Handbook7_Breast-5.pdf

17.  Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database Syst Rev 2011, Issue 1. Art. No.: CD001877. DOI: 10.1002/14651858.CD001877.pub4. onlinelibrary.wiley.com/doi/10.1002/14651858.CD001877.pub4/pdf

18.  Nordic Cochrane Centre, 2012 ‘What you always wanted to know about breast screening’ Accessed February 2012 www.cochrane.dk/screening/mammography-leaflet.pdf

19.  Advisory Committee on Breast Cancer Screening. Screening for Breast Cancer in England: Past and Future. NHSBSP Publication No 61, February 2006 www.cancerscreening.nhs.uk/breastscreen/publications/nhsbsp61.pdf

20.  Yaffe MJ, Mainprize JG. Risk of Radiation-induced Breast Cancer from Mammographic Screening. Radiology 2011; 258: 98-105 radiology.rsna.org/content/258/1/98.abstract

21.  Loughran CF, Keeling C. Seeding of tumour cells following breast biopsy: a literature review. Breast Cancer Research 2010; 12(Suppl 3): 43 breast-cancer-research.com/content/12/S3/P43

 

Chapter 4  Smears and fears: the Jade Goody effect

1.    Weaver M. Tributes pour in for Jade Goody after reality star dies from cancer, aged 27. Guardian, March 2009 www.guardian.co.uk/media/2009/mar/22/jade-goody-dies-tributes

2.    Cancer Research UK. Preventing cervical cancer. April 2004 www2.units.it/brancaleone/leaflet_cervical_apr04.pdf

3.    NHS Scotland. The Cervical Screening Test. Put it on Your List. 2010 www.healthscotland.com/uploads/documents/13485-TheCervicalScreeningTest.pdf

4.    Raffle AE, Alden B. Outcomes of screening to prevent cancer: analysis of cumulative incidence of cervical abnormality and modelling of cases and deaths prevented. BMJ 2003; 326 : 901 www.ncbi.nlm.nih.gov/pmc/articles/PMC153831/

5.    Crane JM. Pregnancy outcome after loop electrosurgical excision procedure: a systematic review. Obstet Gynecol. 2003;102: 1058-62. www.sciencedirect.com/science/article/pii/S0029784403007415

6.    Samson SL, Bentley JR. The effect of loop electrosurgical excision procedure on future pregnancy outcome. Obstet Gynecol. 2005;105: 325-32. journals.lww.com/greenjournal/Abstract/2005/02000/The_Effect_of_Loop_Electrosurgical_Excision.19.aspx

7.    Cancer Research UK. Cervical cancer statistics-UK info.cancerresearchuk.org/cancerstats/types/cervix/incidence/

8.    Office of National Statistics. Cancer Trends in England and Wales, 1950-1999, Chapter 6 http://www.ons.gov.uk/ons/rel/cancer-unit/cancer-trends-in-england-and-wales/smps-no–66/index.html

9.    Papanicolaou GN, Traut HF. Diagnosis of uterine cancer by vaginal smear. Oxford: Commonwealth Fund, Oxford University, 1943.

10.  Lund, CJ. An Epitaph for Cervical Carcinoma. JAMA. 1961;175(2):98-99 jama.ama-assn.org/content/175/2/98.abstract

11.  Debates about cervical screening: an historical overview. J Epidemiol Community Health 2008; 62:284-287 jech.bmj.com/content/62/4/284.extract

12. Clarke EA, Anderson TW. Does screening by ‘PAP’ smears help prevent cervical cancer? A Case-control Study. Lancet. 1979; 314: 8132. www.ncbi.nlm.nih.gov/pubmed/87887

13.  Apostolides A, Henderson M. Evaluation of Cancer Screening Programs. Parallels with Clinical Trials. Cancer 1977; 39:1779-1785. onlinelibrary.wiley.com/doi/10.1002/1097-0142(197704)39:4%2B%3C1779::AID-CNCR2820390805%3E3.0.CO;2-9/pdf

14.  Peto J, Gilham C. The cervical cancer epidemic that screening has prevented in the UK. Lancet 2004; 364, 249 – 256 www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)16674-9/fulltext

15.  NHS Cervical Screening Programme. Cervical screening saves thousands of lives. July 2004 cancerscreening.nhs.uk/cervical/news/010.html

16.  Modernising the NHSCSP: Introduction of LBC and change in national policy, NHS Cervical Screening Programme, 22/10/03 cancerscreening.nhs.uk/cervical/news/009.html

17.  Jacobs K. Why should we be refused a smear test? Guardian; March 2009 www.guardian.co.uk/commentisfree/2009/mar/05/health-health

18.  Marie Stopes International. Marie Stopes International welcomes government review of the UK’s cervical screening policy. March 2009 www.mariestopes.org.uk/PressReleases/UK/Marie_Stopes_International_welcomes_government_review_of_the_UK%E2%80%99s_cervical_screening_policy.aspx

19.  Advisory Committee on Cervical Screening. Extraordinary Meeting to re-examine current policy on cervical screening for women aged 20-24 years taking account of any new evidence and to make recommendations to the National Cancer Director and Ministers. May 2009 www.cancerscreening.nhs.uk/cervical/cervical-review-minutes-20090519.pdf

20.  Simsir A, Brooks S. Cervicovaginal smear abnormalities in sexually active adolescents. Implications for management. Acta Cytol. 2002; 46:271-6. www.acta-cytol.com/toc/auto_abstract.php?id=16049

21.  Robertson JH, Woodend BE. Risk of cervical cancer associated with mild dyskaryosis BMJ 1988; 297: 18-21 www.bmj.com/content/297/6640/18.short

22.  Sasieni P, Castanon A. Effectiveness of cervical screening with age: population based case-control study of prospectively recorded data. BMJ 2009; 339:b2968 www.bmj.com/content/339/bmj.b2968

 

Chapter 5  Screening for more: the prostate, bowel and aorta

1.    Abbasi K. To screen or not to screen? BMJ 1998; 316 : 484 www.bmj.com/content/316/7129/484.full

2.    Thompson IM, Ankherst DP. Prostate-specific antigen in the early detection of prostate cancer. CMAJ 2007; 176: 1853-1858 www.cmaj.ca/content/176/13/1853.full

3.    Albin RJ. The Great Prostate Mistake. New York Times, March 2010.  www.nytimes.com/2010/03/10/opinion/10Ablin.html

4.    Lefevre ML. Prostate Cancer Screening: More Harm Than Good? Am Fam Physician 1998 Aug 1;58(2):432-438 www.aafp.org/afp/1998/0801/p432.html

5.    Schröder FH, Hugosson J. Screening and Prostate-Cancer Mortality in a Randomized European Study. N Engl J Med 2009; 360:1320-1328 www.nejm.org/doi/full/10.1056/NEJMoa0810084

6.    Andriole GL, Crawford ED. Mortality Results from a Randomized Prostate-Cancer Screening Trial. N Engl J Med 2009; 360:1310-1319 www.nejm.org/doi/full/10.1056/NEJMoa0810696

7.    Lin K, Lipsitz R. Benefits and Harms of Prostate-Specific Antigen Screening for Prostate Cancer. Agency for Healthcare Research and Quality (US), August 2008. www.annals.org/content/149/3/192.abstract

8.    Barry MJ. Early Detection and Aggressive Treatment of Prostate Cancer. J Gen Intern Med 2000; 15: 749–751 www.ncbi.nlm.nih.gov/pmc/articles/PMC1495598/

9.    Barry MJ, Mulley Jr AJ. Why Are a High Overdiagnosis Probability and a Long Lead Time for Prostate Cancer Screening So Important? J Natl Cancer Inst 2009; 101: 374-383. jnci.oxfordjournals.org/content/101/6/362.long

10.  Stamey TA, Yang N. Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate. N Engl J Med 1987; 317:909-916 www.nejm.org/doi/full/10.1056/NEJM198710083171501

11.  Baker B. Medicare’s new PSA coverage, revised CPT lab panels. ACP–ASIM Observer, February 2000 www.acpinternist.org/archives/2000/02/qanda.htm

12.  Melia J, Moss S. Survey of the rate of PSA testing in general practice. Brit J Cancer 2001; 85; 656–657 www.ncbi.nlm.nih.gov/pmc/articles/PMC2364127/pdf/85-6691962a.pdf

13.  Franks LM, Latent Carcinoma of the Prostate, J Pathol Bacteriol, 68,2,603-606.

14. Baker M, Standford Report, 22/9/04 Common test for prostate cancer comes under fire news.stanford.edu/news/2004/september22/med-prostate-922.html

15.  Stamey TA, Caldwell M. The Prostate Specific Antigen Era in the United States is over for Prostate Cancer: What Happened in the Last 20 Years? J Urol, 172: 1297-1301 www.jurology.com/article/S0022-5347(05)61155-X/abstract

16.  Rich AR, On the frequency of occurance of occult carcinoma of the prostate.  The Journal of Urology, 33:3 1935. ije.oxfordjournals.org/content/36/2/274.full.pdf+html

17. A Tale of Two Brothers. The Prostate Centre, London, 2011 www.theprostatecentre.com/prostate-centre-patients/patient-stories/a-tale-of-two-brothers

18.  NHS Bowel Cancer Screening Pilot, 2007. www.cancerscreening.nhs.uk/bowel/pilot.html

19.  NHS Cancer Screening Programmes Bowel Cancer Screening. The colonoscopy Investigation www.cancerscreening.nhs.uk/bowel/publications/colonoscopy-investigation.pdf

20.  Hewitson P, Glasziou P. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. 2008, John Wiley & Sons onlinelibrary.wiley.com/doi/10.1002/14651858.CD001216.pub2/abstract

21. The NHS Abdominal Aortic Aneurysm Screening Programme. Information for Healthcare Professionals. aaa.screening.nhs.uk/professionals

22.  Thompson SG, Ashton HA. Screening men for abdominal aortic aneurysm: 10 year mortality and cost effectiveness results from the randomised Multicentre Aneurysm Screening Study. BMJ 2009; 338:b2307 www.bmj.com/content/338/bmj.b2307?view=long&pmid=19553269

23.  Schlösser FJ, Vaartjes I. Mortality after elective abdominal aortic aneurysm repair. Ann Surg 2010;251:158-64. journals.lww.com/annalsofsurgery/Abstract/2010/01000/Mortality_After_Elective_Abdominal_Aortic_Aneurysm.24.aspx

24.  Irvine CD, Shaw E. A Comparison of the Mortality Rate After Elective Repair of Aortic Aneurysms Detected Either by Screening or Incidentally. Eur J Vasc Endovasc Surg; 20: 374-378  www.sciencedirect.com/science/article/pii/S1078588400911870

25.  Beck AW, Goodney PP. Predicting 1-year mortality after elective abdominal aortic aneurysm repair, J Vasc Surg 49;4:838-844, April 2009 http://www.jvascsurg.org/article/S0741-5214(08)01880-6/abstract

26.  Khaira HS, Herbert LM. Screening for abdominal aortic aneurysms does not increase psychological morbidity. Ann R Coll Surg Engl 1998; 80: 341–342 www.ncbi.nlm.nih.gov/pmc/articles/PMC2503123/?page=1

27.  Lifeline Screening. Screening for abdominal aortic aneurysm. www.lifelinescreening.co.uk/health-screening-services/abdominal-aortic-aneurysm.aspx

 

Chapter 6  Health for sale: everyone wants a slice of the healthy patient

1.    Hope J. Low-cholesterol spread ‘not certain to cut heart risks’, GPs told. Daily Mail, May 2008. www.dailymail.co.uk/health/article-1023212/Low-cholesterol-spread-certain-cut-heart-risks-GPs-told.html

2.    Florahearts.co.uk. Frequently asked questions. www.flora-professional.co.uk/plant_sterols.asp

3.    Shepherd J, Cobbe SM. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. New Eng J Med 1995; 333: 1301-1307 www.nejm.org/doi/full/10.1056/NEJM199511163332001

4.    www.framinghamheartstudy.org/

5.    Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994; 344:1383-9. www.thelancet.com/journals/lancet/article/PIIS0140-6736(94)90566-5/abstract

6.    Flora pro-activ. Lowering your Cholesterol, September 2009. 162.61.226.126/pdf/Lowering%20Your%20Cholesterol.pdf

7.    Flora pro-activ. Plant Sterols Scientific Review, June 2009. www.flora-professional.co.uk www.flora-professional.co.uk/pdf/The%20science%20behind%20plant%20sterols_Scientific%20reviews%20(long%20version).pdf

8.    Danone. What is Activia? www.activia.ie www.activia.ie/index.php/activia-explained/what-is-activia/5

9.    Probiotics in Practice. www.probioticsinpractice.co.uk/introduction-to-probiotics.aspx

10.  Danone Research. Clinical Studies. www.studies.danone.com/

11.  Guyonneta D,  Schlumberger A. Fermented milk containing Bifidobacterium lactis DN-173 010 improves gastrointestinal well-being and digestive symptoms in women reporting minor digestive symptoms: a randomised, double-blind, parallel, controlled study. Br J Nutrition 2009; 102: 1654-1662 journals.cambridge.org/action/displayAbstract?fromPage=online&aid=6731400

12.  Guyonnet D, Woodcock A. Fermented milk containing Bifidobacterium lactis DN-173 010 improved self-reported digestive comfort amongst a general population of adults. A randomized, open-label, controlled, pilot study. J Digestive Diseases 2009; 10: 61-70 onlinelibrary.wiley.com/doi/10.1111/j.1751-2980.2008.00366.x/abstract

13.  Agrawal A, Houghton LA. Clinical trial: the effects of a fermented milk product containing Bifidobacterium lactis DN-173 010 on abdominal distension and gastrointestinal transit in irritable bowel syndrome with constipation. Alimentary Pharmacology & Therapeutics 2009; 29:104–114. onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2008.03853.x/abstract

14.  Guyonnet D, Chassany O. Effect of a fermented milk containing Bifidobacterium animalis DN-173 010 on the health-related quality of life and symptoms in irritable bowel syndrome in adults in primary care: a multicentre, randomized, double-blind, controlled trial. Alimentary Pharmacology & Therapeutics 2007; 26:475–486. onlinelibrary.wiley.com/doi/10.1111/j.1365-2036.2007.03362.x/abstract

15.  Advertising Standards Authority. ASA Adjudication on Coca-Cola Great Britain, October 2009. www.asa.org.uk/ASA-action/Adjudications/2009/10/Coca_Cola-Great-Britain/TF_ADJ_47037.aspx

16.  De-Regil LM, Fernández-Gaxiola AC. Effects and safety of periconceptional folate supplementation for preventing birth defects. Cochrane Database Syst Rev. 2011; 10: CD007950 onlinelibrary.wiley.com/doi/10.1002/14651858.CD007950.pub2/pdf

17.  Irlam JH, Visser MME. Micronutrient supplementation in children and adults with HIV infection. Cochrane Database Syst Rev. 2010; 12: CD003650 apps.who.int/rhl/reviews/CD003650.pdf

18.  Caraballoso M, Sacristan M. Drugs for preventing lung cancer in healthy people. Cochrane Database Syst Rev. 2003; 2: CD002141 onlinelibrary.wiley.com/doi/10.1002/14651858.CD002141/pdf

19.  Bjelakovic G, Nikolova N. Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev. 2008; 2: CD007176 onlinelibrary.wiley.com/doi/10.1002/14651858.CD007176/pdf/standard

20.  Mishell DR. Goodwin TM, Brenner PF. Management of common problems in obstetrics and gynecology (fourth edition), Blackwell 2002

21.  Babystart Pre-conception fertility fertilityshop.com/shop/index.php?main_page=product_info&cPath=1&products_id=15

22.  Aboulghar MA, Mansour RT. Diagnosis and management of unexplained infertility: an update. Arch Gynecol Obstet 2003; 267:177-188 www.springerlink.com/content/6bfr0hc8kngget8f/

23.  Guzick DS, Overstreet JW. Sperm morphology, motility and concentration in fertile and infertile men. N Engl J Med 2001; 345:1388-1393 www.nejm.org/doi/full/10.1056/NEJMoa003005#t=articleDiscussion

24.  Zita West  www.zitawest.com/about-zita-west-fertility-clinic/

25.  The Zita West Fertility MOT  www.zitawest.com/buy/services/tests/fertility-mot-amh-diy-test-kit.htm.htm

26.  Reproductive Ageing. Royal College of Obstetricians and Gynaecologists, 2010

27.  Nuffield Health, Fertility MOT, accessed Feburary 2012 www.nuffieldhealth.com/treatments/fertility-mot

28.  Ritchie G. Fertility MOT made wannabe mum realise she had to get a move on if she wanted to conceive. The Daily Record, Jun 2010. www.dailyrecord.co.uk/news/real-life/2010/06/04/fertility-mot-made-wannabe-mum-realise-she-had-to-get-a-mo

29.  Boots. Cervical Cancer Vaccination. www.boots.com/en/Cervical-Cancer-Vaccination_1150826/

30.  ASCCP. Practice Management. Natural History of HPV www.asccp.org/practicemanagement/hpv/naturalhistoryofhpv/tabid/5962/default.aspx

31.  Paavonen J, Naud P. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009; 374: 301–314 www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)61248-4/fulltext

32.  FUTURE II Study Group. Quadrivalent Vaccine against Human Papillomavirus to Prevent High-Grade Cervical Lesions. N Engl J Med 2007; 356:1915-1927 www.nejm.org/doi/full/10.1056/NEJMoa061741

33.  Sigurdsson R, Briem H. The efficacy of HPV 16/18 vaccines on sexually active 18–23 year old women and the impact of HPV vaccination on organized cervical cancer screening. Acta Obstetrica et Gynecologica Scandinavia, 2009, Vol 8, Pages 27-35 informahealthcare.com/doi/abs/10.1080/00016340802566770

 

Chapter 7  George Clooney and the medical certainty illusion

1     Rorke B, Pathologic diagnosis as the gold standard. Cancer. 1997 Feb 15;79(4):665-7. www.ncbi.nlm.nih.gov/pubmed/9024702

2.    Presant CA, Russell WO, Alexander RW, Fu YS. Soft-tissue and bone sarcoma histopathology peer review: the frequency of disagreement in diagnosis and the need for second pathology opinions. The Southeastern Cancer Study Group experience.  J Clin Oncol 1986; 4:1658 – 1661 jco.ascopubs.org/content/4/11/1658.abstract

3.    Baak JPA, Lindeman J, Overdiep SH, Langley FA. Disagreement of histopathological diagnoses of different pathologists in ovarian tumors – with some theoretical considerations. Eur J Obstet Gyn R B 1982; 13(1):51-55. www.sciencedirect.com/science/article/pii/0028224382900375

4.    Farmer ER, Gonin, R, Hanna MP. Discordance in the histopathologic diagnosis of melanoma and melanocytic nevi between expert pathologists. Hum Pathol. 1996; 27(6): 528-531 www.ncbi.nlm.nih.gov/pubmed/8666360

5.    Swerlick RA, Solomon ARR. Clinical diagnosis of moles vs Melanoma. JAMA 1998; 280(10):881-882 jama.ama-assn.org/content/280/10/881.extract

6.    Vishal, K. Frequency and clinical importance of pathological discordance in lymphoma. University of Toronto 2009; 151 https://tspace.library.utoronto.ca/bitstream/1807/18799/6/Kukreti_Vishal_200911_MSc_thesis.pdf

7.    Gill C, Sabin L. Why clinicians are natural Bayesians. BMJ 2005; 330:1080 www.bmj.com/content/330/7499/1080.extract

8.    Morris AH. Developing and implementing computerized protocols for standardization of clinical decisions. Ann Intern Med 2000; 132(5):373-383 www.annals.org/content/132/5/373.abstract

9.   Garg AX, Adhikari NK. Effects of computerized clinical decision support systems on practitioner performance and patient outcomes. JAMA 2005; 293(10):1223-1238 jama.ama-assn.org/content/293/10/1223.short

 

Chapter 8  The snowballing of protocols

1.    Morrell CJ, Munro J.Impact of NHS Direct on other services: the characteristics and origins of its nurses. Emerg Med J 2002; 19:337-340 emj.bmj.com/content/19/4/337.long

2.    Munro  J, Nicholl J. Evaluation of NHS Direct first wave sites. First interim report to the Department of Health, University of Sheffield 1998 www.shef.ac.uk/polopoly_fs/1.43643!/file/nhsd1.pdf

3.    Dealing with a patient who has a 10-year smear gap. Pulse Today. November 2011 www.pulsetoday.co.uk/main-content/-/article_display_list/10874619/www.pulsetoday.co.uk/main-content/-/article_display_list/10874619/dealing-with-a-patient-who-has-a-10-year-smear-gap

4.    Uitti RJ, Calne DB, Dickson DW, Wszolek ZK. Is the neuropathological ‘gold-standard’ diagnosis dead? Implications of clinicopathological findings in an autosomal dominant neurodegenerative disorder. Parkinsonism & Related Disorders 2004; 10(8):461-463

5.    Rivett G, How is General Practice funded? www.nhshistory.net/gppay.pdf

6.    Parker G. Is depression overdiagnosed? Yes. BMJ, 2007;335:328 August 2007. www.bmj.com/content/335/7615/328.full

7.    Healy D. The anti-depressant era. Cambridge, MA: Harvard University Press,1997.

8.    The NHS Information Centre Prescribing Support Unit. Prescriptions dispensed in the community, statistics for 1999 to 2009: England. The Health and Social Care Information Centre, 2010. www.ic.nhs.uk/

9.    Coyne JC, Schwenk TL. The relationship of distress to mood disturbance in primary care and psychiatric populations. J Consult Clin Psychol 1997; 65(1):161-168 psycnet.apa.org/journals/ccp/65/1/161/

10. Kessler D, Bennewith O. Detection of depression and anxiety in primary care: follow up study. BMJ 2002; 325(7371):1016-1017 www.bmj.com/content/325/7371/1016.1.full.pdf

11.  Phelan E, Williams B. A study of the diagnostic accuracy of the PHQ-9 in primary care elderly. BMC Fam Pract 2010; 11:63 www.biomedcentral.com/1471-2296/11/63/abstract

12.  Kroenke K, Spitzer RL. The PHQ-9 Validity of a brief depression severity measure. J Gen Intern Med. 2001; 16(9):606-613 www.ncbi.nlm.nih.gov/pmc/articles/PMC1495268/?tool=pubmed

13.  Cameron IM, Crawford JR. Psychometric comparison of PHQ-9 and HADS for measuring depression severity in primary care. Br Gen Pract. 2008; 58(546):32-36. www.ncbi.nlm.nih.gov/pmc/articles/PMC2148236/?tool=pubmed

14.  Cameron IM, Lawton K. Appropriateness of antidepressant prescribing: an observational study in a Scottish primary-care setting. Br Gen Pract 2009; 59(566):644-649 www.ncbi.nlm.nih.gov/pmc/articles/PMC2734353/?tool=pubmed

 

Chapter 9  Who decides what doctors do: pharma, politicians of patients?

1.    Doll R, Hill AB. Smoking and Carcinoma of the Lung. BMJ 1950; 2(4682):739-748 www.bmj.com/content/2/4682/739.full.pdf

2.    Stead LF, Bergson G. Physician advice for smoking cessation. Cochrane Database Syst Rev. 2008; 16(2) www.thecochranelibrary.com/userfiles/ccoch/file/World%20No%20Tobacco%20Day/CD000165.pdf

3.    Doll R, Peto R. Mortality in relation to smoking: 50 years’ observations on male British Doctors. BMJ 2004; 328(7455) www.bmj.com/content/328/7455/1519.full

4.    House of Commons Health Committee. The influence of the pharmaceutical industry. Fourth Report of Session 2004-2005 www.publications.parliament.uk/pa/cm200405/cmselect/cmhealth/42/42.pdf

5.    Gagnon M-A, Lexchin J. The cost of pushing pills: a new estimate of pharmaceutical promotion expenditures in the United States. PLoS Medicine 2008; 5(1) www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.0050001

6.    IMS. New Models, New Metrics – website accessed February 2012 www.imshealth.com

7.    Matyas V. Protecting the identity of doctors in drug prescription analysis. Health Informatics Journal 1998, 4(3):205-209 jhi.sagepub.com/content/4/3-4/205

8.    Panush RS. Why I no longer accept pens (or other “gifts” from Industry (and why you shouldn’t either). J Rheumatol 2003;31:8 www.jrheum.com/subscribers/04/08/tables/PDF/2004-38.aug.pdf

9.    Fischer MA, Keough ME. Prescribers and pharmaceutical representatives: why are we still meeting? J Gen Intern Med. 2009; 24(7):795-801 www.ncbi.nlm.nih.gov/pmc/articles/PMC2695530/?tool=pubmed

10. Spilker B. The benefits and risks of a pack of M&Ms, Health Affairs 2002 content.healthaffairs.org/content/21/2/243.full

11. Caudill TS, Johnson MS. Physicians, pharmaceutical sales representatives, and the cost of prescribing.  Arch Fam Med. 1996; 5:201-206 archfami.ama-assn.org/cgi/reprint/5/4/201

12. Wazana A. Physicians and the pharmaceutical industry: is a gift ever just a gift? JAMA 2000; 283(3):373-380 jama.ama-assn.org/content/283/3/373.long

13. Irving R. GPs accused of ‘Luddism’ over drugs. The Sunday Times, June 06 2005

14. LaMattina JL. Drug Truths: Dispelling the Myths about Pharma R&D Wiley, 2009

15. Moreno C, Laje G. National trends in the outpatient diagnosis and treatment of bipolar disorder in youth. Arch Gen Psychiatry 2007; 64(9):1032-1039 archpsyc.ama-assn.org/cgi/content/abstract/64/9/1032

16. Zimmerman M, Ruggero CJ. Is bipolar disorder overdiagnosed? J Clin Psychiatry. 2008; 69(6):935-940 www.ncbi.nlm.nih.gov/pubmed/18466044

17. Review of the week: when truth lies buried. BMJ 2010; 340 www.bmj.com/content/340/bmj.c604.extract

18. Pharmaceutical giant AstraZeneca to pay $520 million for off-label drug marketing. The United States Department of Justice, April 2010 www.justice.gov/opa/pr/2010/April/10-civ-487.html

19. AstraZeneca in $198m claim payout. BBC News Business, August 2010 www.bbc.co.uk/news/business-10912302

20. Spielmans CI, Parry PI. From evidence-based medicine to marketing-based medicine: evidence from internal industry documents. Bioethical Inquiry December 2009 i.bnet.com/blogs/spielmans-parry-ebm-to-mbm-jbioethicinqu-2010.pdf

21. Bombardier C, Laine L. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 2000; 343:1520-1528 www.nejm.org/doi/full/10.1056/NEJM200011233432103

22. Topol EJ. Failing the Public Health – Rofecoxib, Merck and the FDA. N Engl J Med 2004; 351:1707-1709. www.nejm.org/doi/full/10.1056/NEJMp048286

23.  Curfman GD, Morrissey S. Expression of Concern: Bombardier et al., ‘Comparison of Upper Gastrointestinal Toxicity of Rofecoxib and Naproxen in patients with Rheumatoid Arthritis”. N Engl J Med 2000; 343:1520-1528. www.nejm.org/doi/full/10.1056/NEJMe058314

24.  Merck News Release, April 28th, 2000 ‘Merck Reconfirms Favourable Cardiovascular Safety of Vioxx’ dida.library.ucsf.edu/pdf/oxx17k10

25. Bresalier RS, Sandler RS. Cardiovascular events associated with Rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352:1092-1102. www.nejm.org/doi/full/10.1056/NEJMoa050493

26. Merck Press Release. Merck announces voluntary worldwide withdrawal of                   VIOXX.  www.merck.com/newsroom/vioxx/pdf/vioxx_press_release_final.pdf

27. Jüni P, Nartey L. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet 2004; 364(9450):2021-2029 www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17514-4/fulltext

28. Vioxx, the implosion of Merck, and the aftershocks at the FDA. Lancet 2004 364;9450:1995-1996 www.thelancet.com/journals/lancet/article/PIIS0140-6736(04)17523-5/fulltext

29.  Newman M. The Rules of Retraction, BMJ 2010; 341: c6985 www.bmj.com/content/341/bmj.c6985

30. Aursnes I, Tvete IF. Suicide attempts in clinical trials with paroxetine randomised against placebo. BMC Med 2005; 3: 14. 2005 www.ncbi.nlm.nih.gov/pmc/articles/PMC1198229/

31. FDA proposes new warnings about suicidal thinking, behaviour in young adults who take antidepressant medications. US Food and Drug administration, May 2007 www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2007/ucm108905.htm

32. Major pharmaceutical firm concealed drug information: GlaxoSmithKline misled doctors about the safety of drug used to treat depression in children. Media Centre 2004. www.ag.ny.gov/media_center/2004/jun/jun2b_04.html

33. Chalmers I. Government regulation is needed to prevent biased under-reporting of clinical trials. BMJ 2004; 329:462 www.bmj.com/content/329/7463/462.2.full

34. Clark B, The Fight of my Life. Hodder, 2007

35. Instant cure-all: cancer drug must be fast-tracked. The Guardian May 2005 www.guardian.co.uk/news/2005/may/22/leaders.comment

36. ABC News, The Top 10 Medical Advances of the Decade. 17/12/09 abcnews.go.com/Health/Decade/genome-hormones-top-10-medical-advances-decade/story?id=9356853&page=5

37. Tuma RS. Trastuzumab trials steal show at ASCO meeting. J Natl Cancer Inst 2005; 97(12):870-871 jnci.oxfordjournals.org/content/97/12/870.full

38. ASCO. Advances in Monoclonal antibody therapy for breast cancer www.asco.org/ascov2/MultiMedia/Virtual+Meeting?&vmview=vm_session_presentations_view&confID=34&sessionID=1708

39. Romond EH, Perez EA. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005; 353:1673-1684 www.nejm.org/doi/full/10.1056/NEJMoa052122

40. Hortobagyi GN. Trastuzumab in the treatment of Breast cancer. N Engl J Med 2005; 353:1734-1736 www.nejm.org/doi/full/10.1056/NEJMe058196

41. Herceptin trastuzumab. Adjuvant Breast cancer treatment clinical study results www.herceptin.com/hcp/treatment/adjuvant/studies.html

42. Guarneri V, Lenihan DJ. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the MD Anderson Cancer Centre experience. J Clin Oncol 2006; 24(25):4107-4115 jco.ascopubs.org/content/24/25/4107.long

43. Riccart-Gebhart MJ, Procter M. Trastuzumab after Adjuvant chemotherapy in HER2-Positive Breast Cancer. N Engl J Med 2005;353:1659-1672 www.nejm.org/doi/full/10.1056/NEJMoa052306

44. Breastcancer.org Corporate Partners  www.breastcancer.org/about_us/supporters/corp_sponsors.jsp

45. Romond EH, Edith MD. Trastuzumab plus adjuvant chemotherapy for Operable HER2-Positive breast cancer. N Engl J Med 2005; 353:1673-1684

46. Dolan A. ‘My mum has breast cancer, please save her’. The Daily Mail, March 2006 www.dailymail.co.uk/health/article-379338/My-mum-breast-cancer-save-her.html

47. McCartney M. Are we educating women to be afraid? Cancerworld www.cancerworld.org/Articles/Issues_32/Best_Cancer_Reporter_Award/Are_we_educating_women_to_be_afraid%3F%

 

Chapter 10  Charities and favourite diseases

1.    New survey reveals severity of stroke still widely underestimated. The Stroke Association, October 2004 www.stroke.org.uk/media_centre/press_releases/new_survey.html

2.    Too many elderly ‘left in pain’. BBC News Online October 2006 news.bbc.co.uk/1/hi/health/6065754.stm

3.    Equity and excellence: liberating the NHS. Terrence Higgins Trust October 2010 www.tht.org.uk/binarylibrary/policy/commissioning-white-paper-response.pdf

4.    Why awareness matters. Target Ovarian Cancer www.targetovariancancer.org.uk/page.asp?section=97&sectionTitle=Raising+awareness+of+ovarian+cancer+symptoms

5.    Written evidence from Arrhythmia Alliance (COM 114). http://www.parliament .uk October 2010 www.publications.parliament.uk/pa/cm201011/cmselect/cmhealth/513/513vw108.htm

6.    Breast cancer campaigning lauded for Herceptin case. Brand Republic, March 2006 www.brandrepublic.com/news/544082/Breast-Cancer-Campaign-lauded-Herceptin-case/?DCMP=ILC-SEARCH

7.    Keiden J. Sucked into the Herceptin maelstrom. BMJ 2007; 334:18 www.bmj.com/content/334/7583/18?variant=full

8.    Breast Cancer Campaign, May 2006 breastcancercampaign.org/

9.    Breast Cancer Network Australia Campaigns  www.bcna.org.au/about-bcna/advocacy/campaigns

10. Herceptin and early breast cancer: a moment for caution. Lancet 2005; 366(9498):1673 www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)67670-2/fulltext

11. Aukland Women’s Health Council, Herceptin  www.womenshealthcouncil.org.nz/Features/Hot+Topics/Herceptin.html

12. British Skin Foundation. About the BSF. www.britishskinfoundation.org.uk/AboutUs.aspx

13. Dr. Nick Lowe Dermatologist. Skin Solutions. www.drnicklowe.com/

14. Heart UK: The Cholesterol Charity www.heartuk.org.uk/index.php?/about_us/heart_uk_partners1/

15. IBS Network. Our partners. www.theibsnetwork.org/ourpartners.asp

16. Breast Cancer Breakthrough. Partner your brand with us. www.breakthrough.org.uk/corporate_partners/work_with_us/

17. Breast Cancer Breakthrough. Financial Support 2008/09.  www.breakthrough.org.uk/corporate_partners/work_with_pharmaceutical_companies/financial_support_09.html

18. Trustee’s report and financial statements. Parkinson’s Disease Society of the United Kingdom (Parkinson’s UK), December 2009 www.parkinsons.org.uk/docs/annualreport2009.pdf

19.  GlaxoSmithKline, Responsibility, Commitment to transparency. Patient group funding. Accessed February 2012  www.gsk.com/responsibility/patient-groups/uk-po-asthma-uk.htm

20. Asthma UK, Corporate Gold and Silver. Accessed February 2012 www.asthma.org.uk/corporate_partners/corporate_gold_and_s.html

21.  www.diabetes.org.uk/Diabetes-UK-Professional-Conference/Registration/Information-on-funding

22.  GSK. Patient group funding www.gsk.com/responsibility/patient-groups/uk-po-diabetes-uk.htm

23. Letter to The Times, 24/2/10 Patient wellbeing at risk from substituted generic medicines. http://www.thetimes.co.uk/tto/opinion/letters/article2072558.ece

24.  McCartney M. Generic drugs: protest group was not quite what it seemed. BMJ 2010; 340:c1514 www.bmj.com/content/340/bmj.c1514.full

25.  Ball DE, Tisocki K. Advertising and disclosure of funding on patient organisation websites: a cross-sectional survey. BMC Public Health 2006; 6:201 www.ncbi.nlm.nih.gov/pmc/articles/PMC1557495/

26.  Vermeulen M, Bouma J. The influence of the pharmaceutical industry in patient organisations. Ned Tijdschr Geneeskd 2007; 151(44):2432-2434 www.ncbi.nlm.nih.gov/pubmed/18064861

27.  Jones K. In whose interest? Relationships between health consumer groups and the pharmaceutical industry in the UK. Sociol Health Illn 2008; 30(6):929-943 www.ncbi.nlm.nih.gov/pubmed/18761512

28.  CoppaFeel! coppafeel.org/page/boobcheck

29.  Male Cancer Awareness Campaign www.malecancer.org/abouts

30.  Who’s in the House? Male Cancer Awareness Campaign, March 2010 www.malecancer.org/featured_articles/item/14

31.  Information on Testicular Cancer, Orchid: Fighting Male Cancer Leaflets. www.orchid-cancer.org.uk/453/Know-Your-Balls-Check-em-Out

32.  Macmillan Cancer Information  www.macmillan.org.uk/Cancerinformation/Cancertypes/Testes/Symptomsdiagnosis/Checkum.aspx

33. McCartney, M. How useful are lifetime risks of disease? BMJ 2011; 342 doi: 10.1136/bmj.d1046 www.bmj.com/content/342/bmj.d1046

34.  Phillips KA, Glendon G. Putting the risk of breast cancer in perspective. N Engl J Med  1999; 340(2): 141-144 www.nejm.org/doi/full/10.1056/NEJM199901143400211

35.  Smith BL, Gadd MA. Perception of breast cancer risk among women in breast centre and primary care setting: correlation with age and family history of breast cancer. Surgery 1996; 120(2): 297-303 www.surgjournal.com/article/S0039-6060(96)80301-1/abstract

36.  Moser K, Patnick J, Beral V. Do women know that the risk of breast cancer increases with age? Brit J Gen Pract, 2007, 57(538) 404-406 www.ncbi.nlm.nih.gov/pmc/articles/PMC2047017/?tool=pubmed

37.  Cummings KM, Lampone D. What young men know about testicular cancer. Prev Med. 1983; 12(2):326-330 www.ncbi.nlm.nih.gov/pubmed/6878194

38.  Moore RA, Topping A. Young men’s knowledge of testicular cancer and testicular self-examination: a lost opportunity? Eur J Cancer Care (Engl) 1999; 8(3): 137-142 onlinelibrary.wiley.com/doi/10.1046/j.1365-2354.1999.00151.x/abstract

39.  Cancer Research UK. Testicular Cancer statistics. info.cancerresearchuk.org/cancerstats/types/testis/

40.  Thomas DB, Gao DL. Randomized trial of breast self-examination in Shanghai: Final results. J Natl Cancer Inst 2002; 94(19):1445-1457 jnci.oxfordjournals.org/content/94/19/1445.long

41.  Cancer Research UK cancer statistics info.cancerresearchuk.org/cancerstats/types/testis/mortality/

42.  Office for National Statistical Bulletin, Suicide Rates in the United Kingdom, 2000-2009 27/1/11 http://www.ons.gov.uk/ons/rel/subnational-health4/suicides-in-the-united-kingdom/2010/index.html

43.  World report chapter 1. Who Int. www.who.int/violence_injury_prevention/publications/road_traffic/world_report/chapter1.pdf

44.  Rachel Stevens ‘gets fruity’ for Everyman. Everyman, June 2005 everyman-campaign.org/News/Press_Archive/2005/13480.shtml

45.  Thornhill JA, Fennelly JJ. Patients’ delay in the presentation of testis cancer in Ireland. Br J Urol. 1987; 59(5):447-451 onlinelibrary.wiley.com/doi/10.1111/j.1464-410X.1987.tb04844.x/abstract

46.  Vasudev NS, Joffe JK. Delay in the diagnosis of testicular tumours – changes over the past 18 years. Br Gen Pract. 2004; 54(505):595-597 www.ingentaconnect.com/content/rcgp/bjgp/2004/00000054/00000505/art00008

47.  Khadra A, Oakeshott P. Pilot study of testicular cancer awareness and testicular self-examination in men attending two South London general practices. Fam Pract. 202; 19(3): 294-296 fampra.oxfordjournals.org/content/19/3/294.full

48.  At-risk men ‘unaware’ of cancer threat. BBC News, June 1999 news.bbc.co.uk/1/hi/health/359443.stm

49.  Gascoigne P, Mason MD. Factors affecting presentation and delay in patients with testicular cancer: results of a qualitative study. Psychooncology 1999; 8(2):144-154 onlinelibrary.wiley.com/doi/10.1002/(SICI)1099-1611(199903/04)8:2%3C144::AID-PON349%3E3.0.CO;2-P/abstract

50.  Breakthrough breast cancer. Breast awareness. www.breakthrough.org.uk/breast_cancer/breast_awareness/

51.  The Prostate Cancer Charity. Prostate and prostate cancer FAQs. www.prostate-cancer.org.uk/information/faq

52.  Neate J. Let men make informed choices on prostate cancer screening. The Guardian, December 2010 www.guardian.co.uk/commentisfree/2010/dec/08/prostate-screening-campaign

53.  Prostate Screening Trust www.prostatescreeningtrust.co.uk/

54.  Kao T-C, Cruess DF. Multicentre patient self-reporting questionnaire on impotence, incontinence and stricture after radical prostatectomy. J Urolology 200; 163(3):858-864. www.jurology.com/article/S0022-5347(05)67819-6/abstract

55.  Volk RJ, Hawley ST. Trials of decision aids for prostate cancer screening: a systematic review. Am J Prev Med 2007; 33(5):428-434 www.ajpmonline.org/article/S0749-3797(07)00497-7/abstract

56.  Frosch DL, Kaplan RM. The evaluation of two methods to facilitate shared decision making for men considering the prostate-specific antigen test. J Gen Intern Med 2001; 16(6):391-398 www.ncbi.nlm.nih.gov/pmc/articles/PMC1495230/

57.  For the man in your life . . . ignorance isn’t bliss: a woman’s guide to the prostate. Prostate UK 2004

 

Chapter 11  The problem with PR

1.    Advert in the Guardian newspaper, 2006 www.margaretmccartney.com/blog/?attachment_id=1256&cpage=1#comment-3381

2.    British Heart Foundation. Job vacancy https://jobs.bhf.org.uk/admin/Files/Public/Vacancies/152/User26/Celebrity%20Liaison%20&%20Media%20Officer%20JD%202010.pdf

3.    Hope hits the headlines. British Heart Foundation, February 2011 www.bhf.org.uk/default.aspx?page=12830

4.    Macrae F. Pill that can trick your heart into fixing itself. The Mail Online. February 2011 www.dailymail.co.uk/health/article-1352257/Pill-allows-damaged-hearts-repair-available-seven-years.htm

5.    D’Souza R. British Scientists create miracle pill to mend broken hearts. Manufacturing Digital, 2011. www.manufacturingdigital.com/sectors/british-scientists-create-miracle-pill-mend-broken-hearts

6.    Alleyne R. Recovering from a heart attack could soon be as simple as recovering from a broken leg. The Telegraph February 2011 www.telegraph.co.uk/health/healthnews/8293320/Recovering-from-a-heart-attack-could-soon-be-as-simple-as-recovering-f

7.    British Heart Foundation. The Science. www.bhf.org.uk/research/mending-broken-hearts-appeal/the-science.aspx

8.    Whitcroft I. How a prostate test taught Darth Vader he’s not so invincible after all. Mail Online, December 2009 www.dailymail.co.uk/health/article-1239014/How-prostate-test-taught-Darth-Vader-hes-invincible-all.html

9.    Estee Lauder. Pink Ribbon Collection. www.esteelauder.com.au/cms/about/breast_cancer_awareness_index.tmpl

10. McCartney M. One in four women? FT Health and Science blog, October 2009 blogs.ft.com/healthblog/2009/10/26/one-in-four-women/#axzz1i7p3cJx4

11. Annual report and audited financial statements. Hyperlipidaemia education & atherosclerosis research trust UK (Heart UK), February 2010 www.heartuk.org.uk/images/uploads/aboutuspdfs/Annual_Report_10.pdf

12. Heart UK. Product Approval www.heartuk.org.uk/index.php?/about_us/product_approval/

13. Landmark Study: Pravastatin rapidly reduces risk of heart attacks and saves lives of people with high cholesterol and no previous heart attack. Press Release 15th November 1995 www.gla.ac.uk/departments/vascularbiochemistry/research/woscops/resultsandconclusions/

14. Shepherd J, Cobbe SM. Prevention of Coronary Heart Disease with Pravastatin in Men with Hypercholesterolemia N Eng J Med 1995; 333:1301-1308 www.nejm.org/doi/full/10.1056/NEJM199511163332001

15. Skolbekken J-A. Communicating the risk reduction achieved by cholesterol reducing drugs. BMJ 1998; 316:1956 www.bmj.com/content/316/7149/1956.full

16.  Wald N, Law MR. A strategy to reduce cardiovascular disease by more than 80%. BMJ 2003; 326:1419 www.bmj.com/content/326/7404/1419.full

17.  Smith R. The most important BMJ for 50 years? BMJ 2003: 326 www.bmj.com/content/326/7404/0.7.full

18.  Hippisley-Cox J, Coupland C. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database. BMJ 2010; 340:c2197 www.bmj.com/content/340/bmj.c2197.abstract

19.  Mayer B, Baggio C. Gastroprotective constituents of Salvua officinalis L. Fitoterapia 2009; 80(7): 421-426 www.ncbi.nlm.nih.gov/pubmed/19481590

20.  Is sage the new superfood? Elsevier ‘Flash’ press release, 6/10/09

21.  Boutron I, Dutton S. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010; 303(2):2058-2064 jama.ama-assn.org/content/303/20/2058.short

22.  Berwanger O, Ribeiro RA. The quality of reporting of trial abstracts is suboptimal: survey of major general medical journals. J Clin Epidemiol 2009; 62(4):387-392 www.jclinepi.com/article/S0895-4356(08)00223-0/abstract

23.  Select Committee on science and technology (third report). Chapter 7: Science and the media. Parliament.uk www.publications.parliament.uk/pa/ld199900/ldselect/ldsctech/38/3810.htm

24.  Woloshin S. Schwartz LM. Press releases by academic medical centres: Not so academic? www.annals.org/content/150/9/613.full.pdf+html

25.  Moynihan R, Bero L. Coverage by the news media of the benefits and risks of medications. N Engl J Med 2000; 342:1645-1650 www.nejm.org/doi/full/10.1056/NEJM200006013422206

26.  Find your me spot www.findyourmespot.com/what.htm

27.  Incredibull: Find your me spot campaign  incredibull3.drupalgardens.com/casestudies/bayer-find-your-me-spot

28.  Sleep Well, Live Well www.sleepwelllivewell.co.uk/

29.  www.sleepwelllivewell.co.uk/PATIENT%20LEAFLET.pdf

30.  Incredibull: Live Well, Sleep well  incredibull3.drupalgardens.com/casestudies/lundbeck

31.  Buscemi N, Vandermeer B. The efficacy and safety of exogenous melatonin for primary sleep disorders. J Gen Intern Med 2005; 20(12):1151-1158 www.ncbi.nlm.nih.gov/pmc/articles/PMC1490287/?tool=pubmed

32.  Buscemi N, Vandermeer B. Efficacy and safety of exogenous melatonin for secondary sleep disorders and sleep disorders accompanying sleep restriction: meta-analysis. BMJ 2006; 332:385 www.bmj.com/content/332/7538/385?view=long&pmid=16473858

33. Press Release. MMYM Launches New Chlamydia Screening Programme in Shropshire. 21/10/10 www.pressbox.co.uk/detailed/Health/MMYM_Launches_New_Chlamydia_Screening_Programme_in_Shropshire_562786.html

34. The Comptroller and Auditor General. Young people’s sexual health: the National chlamydia screening programme. National Audit Office, November 2009 www.nao.org.uk/publications/0809/young_peoples_sexual_health.aspx

35. Low N, Bender N. Effectiveness of chlamydia screening: systematic review. Int J Epidemiol 2009; 38(2):435-448 ije.oxfordjournals.org/content/38/2/435.abstract

36. O’Reilly E. Mpad wins Chlamydia testing brief. PR Week, 20 October 2008 www.prweek.com/uk/news/854935/Mpad-wins-chlamydia-testing-brief/

37. www.sandyford.org/media/113992/sexual%20and%20reproductive%20health%20primary%20care%20guidelines.pdf

38.  Akande V, Turner C. Impact of Chlamydia Trachomatis in the reproductive setting: British Fertility Society guideline for practice. Hum Fertil (CamB). 2010; 13(3):115-125 ukpmc.ac.uk/articles/PMC3069694

30. Frisky not risky chlamydia screening (case study). PMLive Intelligence online, October 2010 www.pmlive.com/pharma_news/frisky_not_risky_223981

 

Chapter 12 Professionals in pay

1.    Press release HARDSPR 2/8/10 stored at www.margaretmccartney.com/blog/?p=1257

2.    Markey CN, Markey PM. A correlational and experimental examination of reality television viewing and interest in cosmetic surgery. Body Image 2010; 7(2):165-171 www.ncbi.nlm.nih.gov/pubmed/20089464

3.    Haas CF, Champion A, Secor D. Motivating factors for seeking cosmetic surgery: a synthesis of the literature. Past Surg Nurs. 2008; 28(4):177-182 journals.lww.com/psnjournalonline/Abstract/2008/10000/Motivating_Factors_for_Seeking_Cosmetic_Surgery__A.6.aspx

4.    Calogero RM, Park LE. Predicting excessive body image concerns among British university students: the unique role of appearance-based rejection sensitivity. Body Image 2010; 7(1): 78-81 www.sciencedirect.com/science/article/pii/S1740144509000977

5.    Veale D. Body dysmorphic disorder. Postgrad Med J 2004; 80:67-71 pmj.bmj.com/content/80/940/67.full

6.    Mya cosmetic vaginal surgery www.mya.co.uk/cosmetic-surgery/vaginal-surgery.php

7.    Castle DJ, Honigman RJ. Does cosmetic surgery improve psychosocial wellbeing? MJA 2002; 176(12): 601-604 www.mja.com.au/public/issues/176_12_170602/cas10571_fm.html

8.    Bruck JC, Kleinschmidt A. Increased self-confidence and decreased sexual discomfort after subpectoral mammoplasty.  Handchir Mikrochir Plast Chir. 2001; 43(2):112-118  www.ncbi.nlm.nih.gov/pubmed/21132627

9.    More magazine Stored at www.margaretmccartney.com/blog/?p=1265

10. Hirsch L. Five secrets to leveraging maximum buying power with your media project. Facial Plastic Surgery Clinics of North America 2010; 18(4): 525-531 www.facialplastic.theclinics.com/article/S1064-7406(10)00092-1/abstract

11. How is general practice funded? NHS History, October 2008 www.nhshistory.com/gppay.pdf

12. Quality and outcomes framework guidance for GMS contract 2011-12. BMA, April 2011 www.nhsemployers.org/Aboutus/Publications/Documents/QOF_guidance_GMS_contract_2011_12.pdf

13. Quality and outcomes framework guidance for GMS contract 2009/2010: delivering investment in general practice. BMA & NHS Employers, March 2009 www.bma.org.uk/images/qof0309_tcm41-184025.pdf

14. Patient Health Questionnaire (PHQ) Screeners. Screener Overview.  www.phqscreeners.com/overview.aspx

15. The PHQ-9 works well as a screening but not a diagnostic instrument for depressive disorder. Evidence Based Mental Health 2010; 13:96 ebmh.bmj.com/content/13/3/96.extract

16. Baker D, Middleton E. Cervical screening and health inequality in England in the 1990s. J Epidemiol Commun H 203; 57:419-423 jech.bmj.com/content/57/6/417.abstract

 

Chapter 13  Political patients

1.    Hart JT. The inverse care law. Lancet. 1971 Feb 27; 1(7696):405-12. www.thelancet.com/journals/lancet/article/PIIS0140-6736(71)92410-X/abstract

2.    Accessing therapy. NHS choices. www.nhs.uk/Livewell/counselling/Pages/Accesstotherapy.aspx

3.    Physiotherapy – Accessing physiotherapy. NHS Choices. www.nhs.uk/Conditions/Physiotherapy/Pages/Accessing-physiotherapy.aspx

4.    Brown JSL, Boardman J. Can a self-referral system help improve access to psychological treatments? Brit J Gen Pract 2010; 60(574):365-371 www.ncbi.nlm.nih.gov/pmc/articles/PMC2858533/?tool=pubmed

5.    Clark DM, Layard R. Improving access to psychological therapy: initial evaluation of two UK demonstration sites. Behav Res Ther 2009; 47(11): 910-920 www.sciencedirect.com/science/article/pii/S0005796709001703

6.    Bowers L. Community psychiatric nurse caseloads and the ‘worried well’: misspent time vital work? J Adv Nurs. 1997; 26(5):930-936 onlinelibrary.wiley.com/doi/10.1046/j.1365-2648.1997.00436.x/abstract

7.    St John-Smith P, McQueen D. The trouble with NHS psychiatry in England. Psychiatric Bulletin 2009; 33:219-225 pb.rcpsych.org/content/33/6/219

8.    Green B. The decline of NHS inpatient psychiatry in England. Priory.com, March 2009 priory.com/psychiatry/Decline_NHS_Inpatient_Psychiatry.htm

9.    The Royal College of Psychiatrists. In-patient services. www.rcpsych.ac.uk/campaigns/fairdeal/whatisfairdeal/in-patientservices.aspx

10. New Roles for psychiatrists. National Working Group on New Roles for Psychiatrists February 2004. www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsPolicyAndGuidance/DH_4073490

11. Pidd H. NHS Direct to be replaced by cut-price health advice service The Guardian, 27.08.2010 www.guardian.co.uk/politics/2010/aug/27/nhs-direct-health-phone-service

12.  Self Care Campaign. About us. Accessed February 2011. www.selfcarecampaign.org/about-us

13.  The Proprietary Association of Great Britain. Market figures www.pagb.co.uk/media/facts.html

14.  Making the case for the self-care of minor elements. PAGB, August 2009 www.pagb.co.uk/publications/pdfs/Minorailmentsresearch09.pdf

15.  Davies P. Darzi centres: an expensive luxury the UK can no longer afford? BMJ 2010; 341 www.bmj.com/content/341/bmj.c6287?papetoc=

16.  Lacobucci G. GP-led health centres ‘dominated by nurses and salaried doctors’. Pulse, Feb 2009 www.pulsetoday.co.uk/newsarticle-content/-/article_display_list/10997436/gp-led-health-centres-dominated-by-nurses-and-salaried-doctors

17.  Lord Darzi’s white elephant legacy. Pulse, 4th Nov 2009. www.pulsetoday.co.uk/main-content/-/article_display_list/11017006/lord-darzi-s-white-elephant-legacy

18.  Irvine M-L. Darzi centres are an expensive instant minor illness service BMJ, 2010 www.bmj.com/rapid-response/2011/11/03/darzi-centres-are-expensive-instant-minor-illness-service

19.  Lacobucci G. Darzi centre dwarfs GMS cash. Pulse, July 2009 www.pulsetoday.co.uk/newsarticle-content/-/article_display_list/11008998/darzi-centre-funding-dwarfs-gms-cash

20.  NHS Choose and book. Clinical responsibilities when delegating actions in NHS choose and book. www.chooseandbook.nhs.uk/staff/communications/fact/clinicalrespons.pdf

21.  Quinn I. Radical new gateways reject one in eight GP referrals. Pulse, February 2011 www.pulsetoday.co.uk/newsarticle-content/-/article_display_list/11053620/radical-new-gateways-reject-one-in-eight-gp

22.  Gateways using nurses to screen GP referrals. Pulse, August 2011 www.pulsetoday.co.uk/main-content/-/article_display_list/12511567/gateways-using-nurses-to-screen-gp-refe

23.  Davies M, Elwyn G. Referral management centres: promising innovations or Trojan Horses? BMJ, 2006; 332:844 www.bmj.com/content/332/7545/844?variant=full

24.  Referral management centres fail to deliver savings, according to new research from The King’s fund. The King’s Fund, August 2010 www.kingsfund.org.uk/press/press_releases/referral_management.html

25.  Potter S, Govindarajulu S. Referral patterns, cancer diagnoses, and waiting times after introduction of two week wait rule for breast cancer: prospective cohort study. BMJ 2007; 335:288 www.bmj.com/content/early/2006/12/31/bmj.39258.688553.55.full

26.  GPRD www.gprd.com/home/

27.  Jones R, Charlton J. Alarm Symptoms and identification of non-cancer diagnoses in primary care: cohort study. BMJ 2009; 339 www.bmj.com/content/339/bmj.b3094.full

28.  Rossing MA, Wicklund KG. Predictive value of symptoms for early detection of ovarian cancer. JNCI 2010; 102(4):222-229 jnci.oxfordjournals.org/content/102/4/222.abstract

29.  Bankhead CR, Collins C. Identifying symptoms of ovarian cancer: a qualitative and quantitative study. BJOG 2008; 115(8):1008-1014 www.ncbi.nlm.nih.gov/pmc/articles/PMC2607526/?tool=pubmed

30. Hamilton W, Lancashire R. The risk of colorectal cancer with symptoms at different ages and between the sexes: a case-control study. BMC Medicine 2009; 7:17 www.biomedcentral.com/1741-7015/7/17

31.  Jones R. Is the two week rule for cancer referrals working? BMJ 2001; 322:1555 www.bmj.com/content/322/7302/1555.full

32.  Thorne K, Hutchings HA. The two-week rule for NHS Gastrointestinal Cancer referrals: A systematic review of diagnostic effectiveness. The Open Colorectal Cancer Journal 2009; 2:27-33 www.biomedcentral.com/1472-6963/6/43

33.  Lewis NR. Jeune IL. Under utilisation of the 2-week wait initiative for lung cancer by primary care and its effect on the urgent referral pathway. British Journal of Cancer 2005; 93:905-908. www.ncbi.nlm.nih.gov/pmc/articles/PMC2361660/

34.  Potter S, Govindarajulu S. Referral patterns, cancer diagnoses, and waiting times after introduction of two week wait rule for breast cancer: prospective cohort study. BMJ 2007; 335:288 www.bmj.com/content/335/7614/288.abstract

35.  Hanna SJ, Muneer A.  The 2-week wait for suspected cancer: a time for rethink? International Journal of Clinical Practice 2005; 59(11):1334-1339 onlinelibrary.wiley.com/doi/10.1111/j.1368-5031.2005.00687.x/full

 

Chapter 14  What sort of patient?

1.    www.nhsdirect.nhs.uk/News/PressReleases/~/media/Files/2007PressReleases/PR_181007_NHSDLaunchesNewPatientSupportProgramme.ashx

2.    Mansell P. The patient paradox. Pharma Times Oct 2010  www.pharmatimes.com/documents/2010/October/the%20patient%20paradox.pdf

3.    Department of Health. Improving Chronic Disease Management.  www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4075213.pdf

4.    National Primary Care Research & Development Centre www.medicine.manchester.ac.uk/primarycare/npcrdc-archive/archive/

5.    Kennedy A, Gately C. Assessing the Process of embedding EPP in the NHS preliminary survey of PCT Pilot sites. National Primary Care Research and Development Centre, January 2004. www.medicine.manchester.ac.uk/primarycare/npcrdc-archive/Publications/EPP%20Report%202004.pdf

6.    Richardson G, Kennedy A. Cost effectiveness of Expert Patients Programme (EPP) for patients with chronic conditions. J Epidemiol Commun H 2008; 62:361-367 jech.bmj.com/content/62/4/361.abstract

7.    Phillips C. What is a QALY? What is…? Series, April 2009 www.medicine.ox.ac.uk/bandolier/painres/download/whatis/QALY.pdf

8.    Foster G, Taylor SJC. Self-management education programmes by lay leaders for people with chronic conditions. The Cochrane Library, Jan 2009 onlinelibrary.wiley.com/doi/10.1002/14651858.CD005108.pub2/pdf/standard

9.    Rogers A, Gately C. Are some more equal than others? Social comparison in self-management skills training for long-term conditions. Chronic Illness 2009; 5(4):305-317 chi.sagepub.com/content/5/4/305.abstract

10.  National Primary Care Research and Development Centre. Expert Patients Programme (EPP): national evaluation. NRCRDC archive site, December 2010. www.medicine.manchester.ac.uk/primarycare/npcrdc-archive/archive/ProjectDetail.cfm/ID/117.htm

11.  Expert Patients Programme. About us www.expertpatients.co.uk/about-us/facts-and-figures

12.  General Medical Council. Duties of a doctor  www.gmc-uk.org/guidance/good_medical_practice/duties_of_a_doctor.asp

13.  Lansley A. Equity and excellence: Liberating the NHS. Press release, July 2010. www.dh.gov.uk/en/MediaCentre/Pressreleases/DH_117360

14.  Office for National Statistics. News release: 9.2 million UK adults have never used the internet. August 2010 http://www.ons.gov.uk/ons/rel/rdit2/internet-access—households-and-individuals/2010/index.html

15.  Hoffman, J. Awash with information, patients face a lonely, uncertain road. New York Times, August 2005 www.nytimes.com/2005/08/14/health/14patient.html?pagewanted=all

16.  General Medical Council. Good Medical Practice: Doctor patient partnership. www.gmc-uk.org/guidance/good_medical_practice/relationships_with_patients_partnership.asp

17.  Department of Health. Liberating the NHS: Greater choice and control. 18/10/10 consultations.dh.gov.uk/choice/choice

18.  Parlimentary questions, Ben Bradshaw, 24/4/98 www.publications.parliament.uk/pa/cm200708/cmhansrd/cm080424/text/80424w0002.htm

19.  Gould M. Claims that NHS choose and book system puts choice before quality. The Guardian, March 2010 www.guardian.co.uk/society/2010/mar/24/hospital-appointments-system-choose-book

20.  Nowottny S. Revealed: Choose and Book to cost taxpayers £210m. Pulse, October 2011. www.pulsetoday.co.uk/newsarticle-content/-/article_display_list/10950416/revealed-choose-and-book-to-cost-taxpayers-210m

21.  Carvel J. Patients to rate and review their GPs on NHS website. The Guardian 2008 www.guardian.co.uk/society/2008/dec/30/doctors-rating-website-nhs

 

Chapter 15  Not more information, better information

1.    NHS Evidence. UK DUETs: A resource to make uncertainties explicit and to help prioritise new research www.library.nhs.uk/DUETs/page.aspx?pagename=UNCERT

2.    Johnson RT, Dickersin K. Publication bias against negative results from clinical trials. Nature Reviews Neurology 2007; 3:590-591 www.nature.com/nrneurol/journal/v3/n11/full/ncpneuro0618.html

3.    Bandyopadhyay S, Bayer AJ. Age and gender bias in statin trials. QJM 2001; 94(3):127-132 qjmed.oxfordjournals.org/content/94/3/127.abstract

4.    Murthy VK, Krumholz HM. Participation in cancer clinical trials. JAMA 2004; 291(22):2720-2726 jama.ama-assn.org/content/291/22/2720.abstract

5.    The NNT (The Number Needed to Treat). Glucocorticoids (steroids) for Croup www.thennt.com/steroids-for-croup/

6.    McMenamin M, Barry H. A survey of breast cancer awareness and knowledge in a Western population: lots of light but little illumination. European Journal of Cancer 2005; 41(3):393-397 www.ejcancer.info/article/S0959-8049(04)00974-8/abstract

7.    Evans R, Edwards A. Reduction in uptake of PSA tests following decision aids: systematic review of current aids and their evaluations. Patient Education and Counselling 2005; 58(1):13-26 www.pec-journal.com/article/S0738-3991(04)00199-5/abstract

8.    Smith SK, Trevena L. A decision aid to support informed choices about bowel cancer screening among adults with low education: randomised controlled trial. BMJ 2010; 341:c5370 www.bmj.com/content/341/bmj.c5370.full

9.    Randomised controlled trial: A decision aid to support informed choice about bowel cancer screening in people with low educational level improves knowledge but reduces screening uptake. Evid Based Nurs 2011; 13 ebn.bmj.com/content/early/2011/02/13/ebn1142.extract

10.  Bekker HL. Decision aids and uptake of screening. BMJ 2010; 341:c5407 www.bmj.com/content/341/bmj.c5407

11.  Arias E. United States life tables, 2006. National Vital Statistics Reports, June 2010. DHHS Publication No. (PHS) 2010-1120 www.cdc.gov/nchs/data/nvsr/nvsr58/nvsr58_21.pdf

12.  Office of National Statistics. Life expectancies at birth and at age 65 in the United Kingdom. 2004-06 to 2008-10 www.ons.gov.uk/ons/dcp171778_238743.pdf

13. McNaughton-Collins M, Fowler FJ. Psychological effects of a suspicious prostate cancer screening test followed by a benign biopsy result. Am J Med 2004; 117(10):719-725 www.amjmed.com/article/S0002-9343(04)00542-X/abstract

14. NHS Scotland, Cervical screening put it on your list booklet, 2010 www.healthscotland.com/uploads/documents/13485-TheCervicalScreeningTest.pdf

15. Boseley S. NICE to lose powers to decide on new drugs. The Guardian, October 2010 www.guardian.co.uk/politics/2010/oct/29/nice-to-lose-new-drug-power

16. National Audit Office. The National programme for IT in the NHS: an update on the delivery of detailed care records systems. HC; 88:2010-2012 www.publications.parliament.uk/pa/cm201012/cmselect/cmpubacc/1070/1070.pdf

17. Pollock AM. Independent sectors treatment centres: evidence so far. BMJ 2008; 336:421 www.bmj.com/content/336/7641/421

18. ISTC Performance Management Analysis. Report to the Department of Health. National centre for health outcomes development, 2004 www.publications.parliament.uk/pa/cm200506/cmselect/cmhealth/934/934awe25.htm

19. Hall C. Foreign surgeons’ work attacked as inferior. The Telegraph, February 2005 www.telegraph.co.uk/news/uknews/1483628/Foreign-surgeons-work-attacked-as-inferior.html

20. Ferris JD. Independent sector treatment centres (ISTCS): early experience from an ophthalmology perspective. Eye 2005; 19:1090-1098 www.nature.com/eye/journal/v19/n10/full/6702007a.html

21. Mason A, Street A. Private sector treatment centres are treating less complex patients than the NHS. J R Soc Med 2010; 103(8):322-331 www.ncbi.nlm.nih.gov/pmc/articles/PMC2913062/?tool=pubmed

22. Clamp JA, Baiju DSR. Do independent sector treatment centres (ISTC) Impact on specialist registrar training in primary hip and knee arthroplasty? Ann R Coll Surg Engl. 2008; 90(6): 492-496 www.ncbi.nlm.nih.gov/pmc/articles/PMC2647243/

23. McGauran A. It’s time to rethink access to GPs within 48 hours, report says. BMJ 2004; 329:762 www.ncbi.nlm.nih.gov/pmc/articles/PMC521032/

24. Committee of Public Accounts. Thirty-fifth report: the refinancing of the Norfolk and Norwich PFI hospital (HC 694). Press Notice 2006; 35: Session 2005-06 www.parliament.uk/business/committees/committees-archive/committee-of-public-accounts/pac030506-pn35/

25. Limb M. PFI deals need more scrutiny after shareholders receive big windfalls. BMJ 2005; 330:1407 www.bmj.com/content/331/7512/343.3

26. Private Finance Initiatives during NHS austerity, Pollock AM, Price D, BMJ 2011; 342:d324 www.bmj.com/content/342/bmj.d324

27. Starr J. Hospital acquired infection. BMJ 2007; 334:708 www.bmj.com/content/334/7596/708.extract

28. NHS National Patient Safety Agency. Clean your hands www.npsa.nhs.uk/cleanyourhands/

29. Dentith M, Shelmerdine T. Organising an awareness week to target hand hygiene practice. Nursing Times 2004; 100(17):36 www.nursingtimes.net/nursing-practice-clinical-research/organising-an-awareness-week-to-target-hand-hygiene-practice/204413.article

30. Department of Health. Uniforms and workwear: an evidence base for developing local policy. September 2007 www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_078435.pdf

31. Sears N. Yo! Middle-aged nurses make cringeworthy Ali G-style rap video to encourage cleanliness. The Daily Mail, September 2010 www.dailymail.co.uk/news/article-1308807/Ali-G-style-rap-video-NHS-staff-branded-absurd-patronising.html

32.  Davies S. Fragmented management, hospital contract cleaning and infection control. Policy & Politics 2010; 38(3):445-463 www.ingentaconnect.com/content/tpp/pap/2010/00000038/00000003/art00008

33.  Backman C, Zoutman DE. An integrative review of the current evidence on the relationship between hand hygiene interventions and the incidence of health care-associated infections. Am J Infection Control 2008; 36(5):333-348 www.ajicjournal.org/article/S0196-6553(07)00812-7/abstract

34.  Trillis F, Eckstein EC. Contamination of hospital curtains with healthcare associated pathogens. Infect Cont Hosp Ep 2008; 29(11) www.jstor.org/stable/10.1086/591863

35.  Clements A, Halton K. Overcrowding and understaffing in modern health-care systems: key determinants in methicillin-resistance Staphylococcus aureus transmission. Lancet Infect Dis 2008; 8(7):427-434 www.ncbi.nlm.nih.gov/pubmed/18582835

36.  Cunningham JB, Kernoham WG. Bed occupancy and turnover interval as determinant factors in MRSA infections in acute settings in Northern Ireland: 1 April 2001 to 31 March 2003. J Hosp Infect 2005; 61(3):189-193 www.ncbi.nlm.nih.gov/pubmed/16153745

37.  Dancer SJ, White LF. Measuring the effect of enhanced cleaning in a UK hospital: a prospective cross-over study. BMC Medicine 2009; 7:28 www.biomedcentral.com/1741-7015/7/28

38.  Health Protection Agency, MRSA, Frequently Asked Questions www.hpa.org.uk/Topics/InfectiousDiseases/InfectionsAZ/StaphylococcusAureus/GeneralInformation/staphFrequentlyAskedQuestions/

39.  Renal Patient View.  https://www.renalpatientview.org/

 

Chapter 16  The unseen benefits of professional healthcare

1.    De Craen AJM, Roos PJ. Effect of colour of drugs: systematic review of perceived effect of drugs and of their effectiveness. BMJ 1996; 313:1624 www.bmj.com/content/313/7072/1624.full

2.    Blackwell B, Bloomfield S. Demonstration to medical students of placebo responses and non-drug factors. Lancet 1972; 229(7763):1279-1282 www.thelancet.com/journals/lancet/article/PIIS0140-6736(72)90996-8/abstract

3.    Moseley JB, O’Malley K. A controlled trial of arthroscopic surgery for osteoarthritis of the knee. N Engl J Med 2002; 347:81-88 www.nejm.org/doi/full/10.1056/NEJMoa013259

4.    Dimond EG, Kittle CF. Comparison of internal mammary artery ligation and sham operation for angina pectoris. Original Research Article Am J Cardiol 1960; 5(4):483-486 www.ajconline.org/article/0002-9149(60)90105-3/abstract

5.    Branthwaite A, Cooper P. Analgesic effects of branding in treatment of headaches. BMJ 1981; 282:1576-1578 www.ncbi.nlm.nih.gov/pmc/articles/PMC1505530/

6.    Desharnais R, Jobin J. Aerobic exercise and the placebo effect: a controlled study. Psychosomatic Medicine 1993; 55(2): 149-154 www.psychosomaticmedicine.org/content/55/2/149.full.pdf

7.    Stovner LJ, Oftedal G. Nocebo as headache trigger: evidence from a sham-controlled provocation study with RF fields. Acta Neurologica 2008; 117(s118): 67-71 onlinelibrary.wiley.com/doi/10.1111/j.1600-0404.2008.01035.x/abstract

8.    Ivan Pavlov – Biography. Nobelprize.org. 28 Oct 2011  www.nobelprize.org/nobel_prizes/medicine/laureates/1904/pavlov-bio.html

9.    Phillips DP, Ruth TE. Psychology and survival. Lancet 1993; 342(8880): 1142-1145 www.sciencedirect.com/science/article/pii/014067369392124C

10. Philips DP, Liu GC. The hound of the baskervilles effect: natural experiment on the influence of psychological stress on timing of death. BMJ 2001; 323(7327): 1443-1446 www.bmj.com/content/323/7327/1443.full

11. Ladwig KH, Roll G. Post-infarction depression and incomplete recovery 6 months after acute myocardial infarction. Lancet 1994; 343(8888):20-23 www.thelancet.com/journals/lancet/article/PIIS0140-6736(94)90877-X/abstract

12.  Blumenthal J, Lett HS. Depression as a risk factor for mortality after coronary artery bypass surgery. Lancet 2003; 362(9384): 604-609 www.thelancet.com/journals/lancet/article/PIIS0140-6736(03)14190-6/fulltext

13. Lindstone SC, Schulzer M. Effects of expectation on placebo-induced dopamine release in Parkinson Disease. Arch Gen Psychiatry 2010; 67(8):857-865 archpsyc.ama-assn.org/cgi/content/full/67/8/857

14. Pollo A, Amanzio M. Response expectancies in placebo analgesia and their clinical relevance. Pain 2001; 93(1):77-84 www.painjournalonline.com/article/S0304-3959(01)00296-2/abstract

15. Grevert P, Albert LH. Partial antagonism of placebo analgesia by naloxone. Pain 1983; 16(2):129-143 www.sciencedirect.com/science/article/pii/0304395983902038

16. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Db of Syst Rev 2010, Issue 1. Art. No.: CD003974. onlinelibrary.wiley.com/doi/10.1002/14651858.CD003974.pub3/pdf/standard

17. Finniss DG, Kaptchuk TJ. Placebo effects: biological, clinical and ethical advances. Lancet 2010; 375(9715): 686-695 www.ncbi.nlm.nih.gov/pmc/articles/PMC2832199/

18. Kaptchuk TJ. Powerful placebo: the dark side of the randomised controlled trial. Lancet 1998; 351: 1722-1725  www.thelancet.com/journals/lancet/article/PIIS0140-6736(97)10111-8/fulltext

19. The Humble Humbug. Lancet 1954; 264(6833):321 www.sciencedirect.com/science/article/pii/S0140673654902457

20. Kaptchuk T, Kelley JM. Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome. BMJ 2008; 336:999  www.bmj.com/content/336/7651/999.full

21. Thomas KB. General practice consultations: is there any point in being positive? BMJ 1987; 294: 1200-1202 www.ncbi.nlm.nih.gov/pmc/articles/PMC1246362/?tool=pubmed

22. Little P, Everitt H. Observational study of effect of patient centeredness and positive approach on outcomes of general practice consultations. BMJ 2001; 323:908 www.bmj.com/content/323/7318/908.abstract

23. Hughes D. Consultation length and outcome in two group general practices. J R Coll Gen Pract. 1983 33(248): 143-144, 146-147 www.ncbi.nlm.nih.gov/pmc/articles/PMC1972718/

24. Campbell SM, Hann M. Identifying predictors of high quality care in English general practice: observational study. BMJ 2001 323:784 www.bmj.com/content/323/7316/784.full

25. Wilson A, Childs S. The relationship between consultation length, process and outcomes in general practice: a systematic review Br Gen Pract. 2002; 52(485):1012-1020 www.ncbi.nlm.nih.gov/pmc/articles/PMC1314474/?tool=pubmed

26. Stirling AM, Wilson P. Deprivation, psychological distress, and consultation length in general practice. Br J Gen Pract. 2001; 51(467)456-460 www.ncbi.nlm.nih.gov/pmc/articles/PMC1314026/

27. Mercer SW, Fitzpatrick B. More time for complex consultations in a high-deprivation practice is associated with increased patient enablement. Br J Gen Pract. 2007; 57(545): 960-966 www.ncbi.nlm.nih.gov/pmc/articles/PMC2084135/?tool=pubmed

28. Linde K, Ramirex G. St John’s Wort for depression – an overview and meta-analysis of randomised clinical trials. BMJ 1996; 313:253 www.bmj.com/content/313/7052/253.full

29. Gratus C, Damery S. The use of herbal medicines by people with cancer in the UK: a systematic review of the literature.  QJM. 2009; 102(12): 831-842 qjmed.oxfordjournals.org/content/102/12/831.abstract

30. Astin JA. Why patients use alternative medicine. JAMA 1998; 279(19): 1548-1553 jama.ama-assn.org/content/279/19/1548.full

31. Turner D, Tarrant C. Do patients value continuity of care in general practice? An investigation using stated preference discrete choice experiments. J Health Serv Res Policy 2007; 12(3):132-137 jhsrp.rsmjournals.com/content/12/3/132.long

32. Kearley KE, Freeman GK. An exploration of the value of the personal doctor-patient relationship in general practice. Br Gen Pract. 2001; 51(470): 712-718 www.ncbi.nlm.nih.gov/pmc/articles/PMC1314098/

33.  Gill JM, Mainous AG. The role of provider continuity in preventing hospitalizations. Arch Fam Med 1998; 7:352-357 archfami.ama-assn.org/cgi/content/full/7/4/352

34.  Cree M, Bell NR. Increased continuity of care associated with decreased hospital care and emergency department visits for patients with asthma. Dis Manag 2006; 9(1):63-71 www.ncbi.nlm.nih.gov/pubmed/16466343

35.  Knight JC, Dowden JJ. Does higher continuity of family physician care reduce hospitalizations in elderly people with diabetes. Popul Health Manag 2009; 12(2):81-6 www.ncbi.nlm.nih.gov/pubmed/19361251

36.  Burge F, Lawson B. Family physician continuity of care and emergency department use in end-of-life cancer care. Med Care 2003; 41(8):992-1001 www.ncbi.nlm.nih.gov/pubmed/12886178

37.  Raddish M, Horn SD. Continuity of care: is it cost effective? Am J Manag C 1995; 5(6):727-734 www.ncbi.nlm.nih.gov/pubmed/10538452

38.  Bamji AN. Southeast London – the unspoken problem. BMJ 2011; 342:d1765 www.bmj.com/content/342/bmj.d1765?tab=full

39.  Mitchell AJ, Vaze A. Clinical diagnosis of depression in primary care: a meta-analysis. Lancet 2009; 374(9690):609-619 www.thelancet.com/journals/lancet/article/PIIS0140-6736(09)60879-5/abstract

40.  Kai J, Crossland A. People with enduring mental health problems described the importance of communication, continuity of care, and stigma. Evid Based Nurs 2002; 5:93 ebn.bmj.com/content/5/3/93.full.pdf

41.  McQueen D, St John Smith P. Psychiatric professionalism, multidisciplinary teams and clinical practice. European Psychiatric Review, 2009;2(2):50-56 www.touchpsychiatry.com/articles/psychiatric-professionalism-multidisciplinary-teams-and-clinical-practice

42.  Craddock N, Antebi D. Wake-up call for British psychiatry. Brit J Psychiat 2008; 193:6-9 bjp.rcpsych.org/content/193/1/6.full

43.  Simmons P, Hawley CJ. Service user, patient, client, user or survivor: describing recipients of mental health services. The Psychiatrist Online 2010; 34:20-23 pb.rcpsych.org/content/34/1/20

44.  Propper C, Burgess S. Competition and quality: evidence from the NHS internal market. www.niesr.ac.uk/event/propper.pdf

45.  Samuel M. NHS Market reforms pose risk to service, warn professionals. Communitycare.co.uk, 24th January 2011 www.communitycare.co.uk/Articles/24/01/2011/116160/NHS-market-reforms-pose-risk-to-services-warn-

46.  Health and social care bill 2011. Royal College of Psychiatrists, Second reading Briefing House of Commons. www.rcpsych.ac.uk/pdf/RCPsych%20Health%20and%20Social%20Care%20Bill%20HOC%202nd%20Reading%20briefing%20-%20final.pdf

 

Chapter 17  Getting back to the right kind of care

1.    Williams B, Poulter NR. British Hypertension Society guidelines. J Hum Hypertens 2004; 18:139-185 www.bhsoc.org/pdfs/BHS_IV_Guidelines.pdf

2.    McInnes GT. Drug treatment of prehypertension: Not now, not ever? Blood Pressure 2009; 18(6):304-307 informahealthcare.com/doi/abs/10.3109/08037050903416436

3.    Pre-diabetes ‘timebomb’ warning. BBC News, October 2009 news.bbc.co.uk/1/hi/health/8310297.stm

4.    The United States of Diabetes: New Report Shows Half the Country Could Have Diabetes or Prediabetes at a Cost of $3.35 Trillion by 2020. United Health Group Newsroom. www.unitedhealthgroup.com/newsroom/news.aspx?id=36df663f-f24d-443f-9250-9dfdc97cedc5

5.    Norris SL, Kansagara D. Screening adults for type 2 diabetes: a review of the evidence for the US preventive services Task Force. Ann Intern Med 2008; 148(11):855-68 www.annals.org/content/148/11/855.abstract

6.    Lily M, Godwin M. Treating prediabetes with metformin. Can Fam Physician 2009; 55(4): 363-369 www.cfp.ca/content/55/4/363.full

7.    Lowther M, Mordue A. Primary prevention of cardiovascular disease in Scotland: we must go further. The Heart Health Network Executive group. January 2006 www.vhscotland.org.uk/library/misc/NHS-CVD%20Full%20Doc.pdf

8.    Marmot M. Social determinants of health inequalities. Lancet 365; 9464:1099-1104, 2005. www.thelancet.com/journals/lancet/article/PIIS0140-6736(05)71146-6/abstract

9.    Fischer PM, Guinan KH. Impact of public cholesterol screening program. Arch Intern Med 1990; 150(12):2567-2572 archinte.ama-assn.org/cgi/content/abstract/150/12/2567

10. Croyle RT, Loftus EF. How well do people recall risk factor test results? Accuracy and bias among cholesterol screening participants. Health Psychol 2006; 25(3):425-32

11.  NHS Health Scotland’s ‘Writing About Health Issues: Voices from Communities’ (2004)

12. Ovarian Cancer: the recognition and initial management of ovarian cancer. NICE, Full Guideline, April 2011. www.nice.org.uk/cg122

13.  Schorge JO. Modesitt SC. SGO white paper on ovarian cancer: Etiology, screening and surveillance. Gynecologic Oncology 2010; 119(1):7-17 www.sciencedirect.com/science/article/pii/S0090825810004300

14.  Mai PL, Wentzensen N. Challenges related to developing serum-based biomarkers for early ovarian cancer detection. Cancer Prev Res 2011; 4:303 cancerpreventionresearch.aacrjournals.org/content/4/3/303.short

15.  National Cancer Institute. Milestone (1971): National Cancer Act of 1971. dtp.nci.nih.gov/timeline/noflash/milestones/m4_nixon.htm

16.  Temel J, Greer J. Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer. NEJM, 2010, 363: 733-742 www.nejm.org/doi/pdf/10.1056/NEJMoa1000678

17. Hitchens C. Topic of Cancer. Vanity Fair, September 2011 www.vanityfair.com/culture/features/2010/09/hitchens-201009

18.  Penson RT, Schapira L. Cancer as Metaphor. The Oncologist 2004; 9(6):708-716 theoncologist.alphamedpress.org/content/9/6/708.full

19.  Petticrew M, Bell R. Influence of psychological coping on survival and recurrence in people with cancer: systematic review. BMJ 2002; 325:1066 www.bmj.com/content/325/7372/1066.1?view=long&pmid=12424165

20. Rapid Response to Petticrew M, Bell R. Influence of psychological coping on survival and recurrence in people with cancer: systematic review, BMJ 2002;325:1066.1 by Benjamin, HH 16/12/02

21. Temel JS, Greer JA. Early palliative care for patients with metastatic non-small-cell lung cancer. N Engl J Med 2010; 363:733-742

22. Comptroller and Auditor General. The provision of out-of-hours care in England, HC 2006; 1041

23. GP Daniel Ubani struck off over fatal overdose. BBC News June 2010 www.bbc.co.uk/news/10349596

24. Select Committee on Health Written Evidence. Memorandum by KernowDoc (GP13). www.publications.parliament.uk/pa/cm200304/cmselect/cmhealth/697/697we12.htm

25.  Concerns over private GP Service. BBC News 21st September 2006 news.bbc.co.uk/1/hi/england/cornwall/5366262.stm

26.  Overseas GP ordered to re-train. BBC News 30th October 2006 news.bbc.co.uk/1/hi/england/cornwall/6099494.stm

27.  NHS 24 ‘changes’ followed deaths. BBC News 30th January 2006 news.bbc.co.uk/1/hi/scotland/4663368.stm

28.  Helpline advice ‘linked to diabetic’s death. BBC News 17th October 2001 news.bbc.co.uk/1/hi/england/1605250.stm

29.  Travis A. Ministers face calls for apology as extent of 1970s ‘virginity tests’ revealed. Guardian 8th May 2011 www.guardian.co.uk/uk/2011/may/08/home-office-virginity-tests-1970s

30.  The doctor cannot always tell: medical examination of the “intact” hymen. Lancet 1978: Feb 18i; 1(8060): 375–6. www.ncbi.nlm.nih.gov/pubmed/75407

31.  McCartney M. Well enough to work? BMJ 2011; 342:d599 www.bmj.com/content/342/bmj.d599?tab=full

32.  Faculty of Occupational Medicine. Good occupational medical practice. August 2010 www.facoccmed.ac.uk/library/docs/p_gomp2010.pdf

33.  Harrington M. An independent review of the work capability. The Stationary Office. November 2010 www.dwp.gov.uk/docs/wca-review-2010.pdf

34. General Medical Council, Fitness to Practice Decisions. 4/10/10 www.gmc-uk.org/concerns/hearings_and_decisions/fitness_to_practise_decisions.asp

35. Management Consultancies Association. Explores the myths about management consulting and the NHS. MCA News  www.mca.org.uk/news/mca-explodes-myths-about-management-consulting-and-nhs

36.  McKinsey & Co. Achieving world class productivity in the NHS 2009/10 –m 2013/14: Detailing the size of the opportunity. Department of Health, March 2009 www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/documents/digitalasset/dh_116521.pdf?utm_source=Sign-Up.to&utm_medium=email&utm_campaign=201250-NHS+Institute+Alert+-+July+2010

37.  Johnson S, Nolan F. Randomised controlled trial of acute mental health care by a crisis resolution team: the north Islington crisis study. BMJ 2005; 331(7517):599 www.bmj.com/content/331/7517/599.abstract

38.  Johnson S, Nolan F. Randomised controlled trial of acute mental health care by a crisis resolution team: the north Islington crisis study. BMJ 2005, Rapid responses.

39.  Gallegos NC, Dawson J. Risk of strangulation in groin hernias. Br J Surg 1991; 78(10):1171-3 www.ncbi.nlm.nih.gov/pubmed/1958976

2 Responses to References

  1. V.Blease says:

    As a “patient” I looked forward to reading this book as I have followed your blog with interest, having heard a particularly perceptive interview you gave on the BBC about patients and their preference for continuity of treatment.
    I was not disappointed. It is a veritable fireworks display and I would love to be able to join the Skeptics Club in Glasgow next Monday when you will be talking about it.
    Perhaps in due course I will feel up to giving you some more specific feedback.. In the meantime
    I hope the book reaches a wide audience, and that even hard-pressed GPs will find time to read and discuss it..Sure isn’t healthy and hearty debate invigorating for all of us?
    Right now I just want to thank you for this list of references which I am sending to friends hoping that it will stimulate them to get copies of their own. It is better than a blurb for conveying the scope of the book.

  2. mgt mccartney says:

    many thanks, glad the references were helpful.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Connecting to %s